GlobeNewswire

Server Technology's HDOT Rack Mount PDU Named 2018 Product of the Year

Dela

Rack PDU Innovation Captures DCS Award's Top Spot Again

RENO, Nev., May 29, 2018 (GLOBE NEWSWIRE) -- Server Technology, a brand of Legrand and a leading provider of intelligent Rack Power Distribution Units a.k.a rack PDU(s), today announced that its High Density Outlet Technology (HDOT) Rack PDUs with Alternating Phase outlet technology has been named a 2018 DCS Awards winner for Data Centre PDU Product of the Year. Continually, DCS Awards judges have singled out the company's server rack power strips for unique benefits--above and beyond standard rack mount PDU solutions - this year marks the fifth year in a row Server Technology has won an award.

The DCS Awards, in association with DataCentre Solutions magazine, are designed to acknowledge product designers, manufacturers, suppliers and providers operating in the data centre arena. For this years awards, Server Technology's patented Alternating Phase outlet technology on the HDOT PDUs, stood out from competitive offerings for its 3-Phase PDU cable management and ability to distribute phased power on a per receptacle basis. The innovation was hailed for providing shorter cable runs that result in better airflow, easier load balancing, and overall greater efficiencies.

According to Jeremy Foroszowsky, Director of Manufacturing Operations and Logistics at Server Technology, "Everything in the data centre is being condensed and there is a never-ending need to fit more into each rack and improve overall efficiencies." Server Technology is addressing this concern with their innovative HDOT PDU that offers maximum density and power, in a smaller form factor that conserves rack space.

However, a large part of the HDOT's true innovation resides within the 10-day customization process. Foroszowsky continues, "Server Technology listens to the needs of our customers, that's why we've aligned our manufacturing and planning processes to ensure we have the right material in-stock to support the configuration requirements of our customer while always maintaining the highest quality standards.  The net result is a superior PDU, that can be custom built via our Build Your Own PDU configurator and shipped in just 10 days. Nobody else is able to provide this level of customized power density to serve individual data centre rack requirements."

In addition to 2018 Product of the Year, DCS Awards named the company:

  • 2017 "Individual of the Year" DCS Award for VP of International Sales, Marc Marazzi
  • 2016 "Data Centre PDU Product of the Year" DCS Award for HDOT
  • 2015 and 2014 "Data Centre Management Product of the Year" DCS Award for Sentry Power Manager (SPM)

"Achieving optimal data centre power management is the goal of every facility and IT manager," said James Giblette, Regional Sales Manager for Server Technology. "Unfortunately, traditional PDU offerings make this an elusive and often complicated goal, because every deployment is different. Server Technology continues to address this issue by enabling customization so that PDUs are tailored to individual rack needs. We are proud to offer a preferred method for optimizing data centre power and honored that the DCS Awards continues to recognize our solutions as the best in the industry."  

For more information please contact lucy.holloway@servertech.com or visit www.servertech.com.

About Server Technology

Server Technology's power strategy experts are trusted to provide Rack PDU solutions for demanding data centres worldwide ranging from small technology startups to Fortune 100 powerhouses. Over 60,000 customers around the world rely on our rack power distribution units to increase density, facilitate capacity planning, improve power monitoring, and drive efficiency. Because power is all we do, you will find us in the best cloud and colocation providers, forward thinking labs and telecommunications operations. Server Technology customers consistently rank us as providing the highest quality PDU(s), the best customer support and most valuable innovation. Let us show you; we have over 12,000 PDU configurations to fit every data centre need and our PDU(s) are shipped within 10 days. Only with Server Technology will customers Stay Powered, Be Supported and Get Ahead. www.servertech.com

About Legrand and Legrand, North and Central America

Legrand is a global specialist in electrical and digital building infrastructures. Its comprehensive offering of solutions for use in commercial, industrial, and residential markets makes it a benchmark for customers worldwide. Innovation for a steady flow of new products with high added value is a prime vector for growth, including, in particular, connected devices stemming from Legrand's global Eliot (Electricity and IoT) program. Legrand reported sales of $6.2 billion(USD) in 2017. Legrand has a strong presence in North and Central America, with a portfolio of well-known market brands and product lines that includes AFCO Systems, C2G, Cablofil, Chief, Da-Lite, Electrorack, Finelite, Luxul, Middle Atlantic Products, Milestone AV, Nuvo, OCL, On-Q, Ortronics, Pass & Seymour, Pinnacle, Projecta, QMotion, Quiktron, Raritan, Sanus, Server Technology, Solarfective, Vaddio, Vantage, Wattstopper, and Wiremold. Legrand is listed on Euronext Paris and is a component stock of indexes including the CAC40, FTSE4Good, MSCI World, ASPI, Corporate Oekom Rating, and DJSI (ISIN code FR0010307819). www.legrand.us

For more information, contact:
Betsey Rogers
Public Relations
BridgeView Marketing
1-603-821-0809
betsey@bridgeviewmarketing.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Server Technology via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum